A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
To evaluate the efficacy of batoclimab compared to placebo as assessed by proptosis and Clinical Activity Score (CAS).
Participants will be randomized 2:1 to receive batoclimab 680 mg SQ for 12 weeks followed by 340 mg SQ for 12 weeks or placebo SQ for 24 weeks. The total study duration is 32 weeks.
Contact Kris Dietzman with questions, (608) 263-9035
For more information about this study, visit: